Get started
KAMADAKK

KAMADA

2,556ILAD
−47−1.81%
At close at Mar 26, 15:24 GMT
ILA
No trades
See on Supercharts
Overview
Financials
News Discussions Technicals Forecast Seasonals

KMDA fundamentals

Key facts

Market capitalization‪1.50 B‬ILS
Dividend yield (indicated)0.00%
Price to earnings Ratio (TTM)24.89
Basic EPS (TTM)1.02ILS
Founded1990
Employees (FY)420
CEOAmir London
Websitekamada.com
About

Kamada Ltd. is a biopharmaceutical company, which focuses on specialty plasma-derived therapeutic. It operates through the Proprietary Products and Distribution segments. The Proprietary Products segment covers the development, manufacture, and sale of plasma-derived protein therapeutics products. The Distribution segment covers the drug products in Israel, which are manufactured by third parties. The company was founded by David Tsur and Ralf Hahn on December 13, 1990 and is headquartered in Rehovot, Israel.

Ownership
‪‪57.51 M‬‬
Free Float shares
‪‪31.07 M‬‬ (54.03%)
Closely held shares
‪‪26.44 M‬‬ (45.97%)
Free Float shares
‪‪31.07 M‬‬ (54.03%)
Closely held shares
‪‪26.44 M‬‬ (45.97%)
Capital structure
Market cap
‪‪1.50 B‬‬
Debt
‪‪40.31 M‬‬
Cash & equivalents
‪‪285.79 M‬‬
Enterprise value
‪‪1.25 B‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪1.50 B‬‬
Price to earning ratio (P/E)
24.89x
Price to sales ratio (P/S)
2.52x
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
24.89x
Price to sales ratio (P/S)
2.52x
Valuation ratios
‪0.00‬
‪0.70‬
‪1.40‬
‪2.10‬
‪2.80‬
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪0.00‬
‪10.00‬
‪20.00‬
‪30.00‬
‪40.00‬
P/E
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪6%‬
‪8%‬
‪10%‬
‪12%‬
‪14%‬
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪0.00‬
‪‪40.00 M‬‬
‪‪80.00 M‬‬
‪‪120.00 M‬‬
‪‪160.00 M‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪0.00‬
‪‪40.00 M‬‬
‪‪80.00 M‬‬
‪‪120.00 M‬‬
‪‪160.00 M‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪0.00‬
‪‪40.00 M‬‬
‪‪80.00 M‬‬
‪‪120.00 M‬‬
‪‪160.00 M‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2024
Proprietary Products
Distribution
By country
Period: 2024
United States
Israel
Latin America
Canada
Europe
Asia
Other

Estimates

Revenue and Earnings forecasts and estimates accuracy

Revenue
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪0.00‬
‪‪45.00 M‬‬
‪‪90.00 M‬‬
‪‪135.00 M‬‬
‪‪180.00 M‬‬
Actual
Estimate
Earnings
Next:May 27, 2025
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪0.00‬
‪0.08‬
‪0.16‬
‪0.24‬
‪0.32‬
Actual
Estimate

Dividends

Dividend yield, history and sustainability

Dividend summary
0.00%
Payout ratio (TTM)
Dividend yield TTM
0.00%
Last payment
0.731
Last ex-date
Mar 17, 2025
Dividend history
‪0%‬
2020
2021
2022
2023
2024
‪0.00‬
Dividends per share (FY)
Dividend yield (FY) %

Financial health

Financial position and solvency of the company

Debt level and coverage
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪‪−100.00 M‬‬
‪0.00‬
‪‪100.00 M‬‬
‪‪200.00 M‬‬
‪‪300.00 M‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪200.00 M‬‬
‪‪400.00 M‬‬
‪‪600.00 M‬‬
‪‪800.00 M‬‬
Assets
Liabilities